Latest Profitability News

SOCO Corporation has returned to profitability in FY25, driven by strategic contract wins and client diversification. The company is now focusing on expanding recurring revenues and leveraging AI and cybersecurity capabilities for future growth.

SOCO Corporation Ltd has reported a return to profitability in FY25, driven by revenue growth and strategic investments. The company is now focused on disciplined execution and client diversification to sustain momentum into FY26.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

Ashley Services reported a challenging FY25 with a 7.3% revenue decline but kicked off FY26 with record quarterly revenues and improved profitability, signaling a strategic turnaround.

Motio Limited has raised $1.73 million through a placement to accelerate its digital display network expansion and repay debt early, aiming to reach profitability sooner.

DigitalX Limited has enhanced its treasury strategy by investing nearly A$5 million into a market-neutral fund while increasing its Bitcoin holdings to over 500 BTC, aiming to balance accumulation with steady income generation.

Atomos Limited has posted its first positive EBITDA quarter since late 2022, driven by strong sales of its flagship Ninja and Shinobi products. The company’s operational overhaul and strategic product launches set the stage for continued growth into Q2 FY26.

The Calmer Co has reported a robust 26% increase in quarterly sales, driven by strong growth in Australia and the US, alongside a significant 39% reduction in cash used in operations, signaling clear progress toward profitability.

Gale Pacific reports stabilising trading conditions in Q1 FY26 with a strategic U.S. operating model overhaul delivering significant cost savings, despite a slight dip in overall sales.

Microba Life Sciences reports robust Q1 FY26 growth in microbiome diagnostics, introduces workflow-enhancing features, and prepares for key therapeutic deal catalysts by year-end.

Microba Life Sciences reports a 145% jump in core microbiome test volumes and is on track to achieve regional break-even by FY26, supported by strategic cost cuts and a $14.5 million capital raise.

X2M Connect Limited kicks off FY26 with a 25% revenue surge and a significant reduction in net debt, backed by major new contracts across Asia and the Middle East.